Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity (2022)
- Authors:
- USP affiliated authors: SILVA, CLOVIS ARTUR ALMEIDA DA - FM ; KUPA, LEONARD DE VINCI KANDA - FM ; LEON, ELAINE PIRES - FM ; BISPO, FABIANA RENATA SOARES - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
- Unidade: FM
- DOI: 10.1007/s10067-022-06134-x
- Subjects: VACINAS VIRAIS; COVID-19; DOENÇAS AUTOIMUNES; ESTUDOS PROSPECTIVOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Clinical rheumatology
- ISSN: 0770-3198
- Volume/Número/Paginação/Ano: v. 41, n. 7, p. 2079-2089, 2022
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
PASOTO, Sandra Gofinet et al. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity. Clinical rheumatology, v. 41, n. 7, p. 2079-2089, 2022Tradução . . Disponível em: https://doi.org/10.1007/s10067-022-06134-x. Acesso em: 12 fev. 2026. -
APA
Pasoto, S. G., Halpern, A. S. R., Guedes, L. K. N., Ribeiro, A. C. M., Yuki, E. N. F., Silva, C. A. A. da, et al. (2022). Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity. Clinical rheumatology, 41( 7), 2079-2089. doi:10.1007/s10067-022-06134-x -
NLM
Pasoto SG, Halpern ASR, Guedes LKN, Ribeiro ACM, Yuki ENF, Silva CAA da, Kupa L de VK, Leon EP, Bispo FRS, Bonfa ESD de O. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity [Internet]. Clinical rheumatology. 2022 ; 41( 7): 2079-2089.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1007/s10067-022-06134-x -
Vancouver
Pasoto SG, Halpern ASR, Guedes LKN, Ribeiro ACM, Yuki ENF, Silva CAA da, Kupa L de VK, Leon EP, Bispo FRS, Bonfa ESD de O. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity [Internet]. Clinical rheumatology. 2022 ; 41( 7): 2079-2089.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1007/s10067-022-06134-x - Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching
- Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control
- Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring
- SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy
- Is uric acid level a predictor of long-term renal outcome in lupus nephritis?
- Antibodies to cellular prion protein and its cognate ligand stress-inducible protein 1 in systemic lupus erythematosus
- Characterizing hand and wrist ultrasound pattern in primary Sjogren's syndrome: a case-control study
- Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
- Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
Informações sobre o DOI: 10.1007/s10067-022-06134-x (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
